COVID-19 Funding Snapshot for Pharma Developers/Manufacturers Views as of August 7, 2020 Presentations August 21, 2020 Lain Anderson Cassie Guo Adam Nover
Contributing authors: Tony Stripling, Associate Consultant Sean Saunders, Life Sciences Speciaist Jennifer Henry, Associate Consultant Patrick Marquet, Associate Related Practice Life Sciences & Pharma The COVID-19 pharmaceutical funding landscape is evolving at a rapid pace, yet several initial insights have emerged 01262022160100
Special Report Life Sciences & Pharma Prescription for Progress: A Health Equity Maturity Framework for Pharma Companies June 12, 2025
Case Study Life Sciences & Pharma Optimizing Four-Wall DC Operations for a Pharmaceutical Distributor March 27, 2025 After years of stable but stagnant warehouse performance, a major pharmaceutical distributor sought to modernize its technology infrastructure to boost…
Executive Insights Life Sciences & Pharma Refining Gross-to-Net Expectations for Improved Strategic Planning November 4, 2024
Published Articles Business Services What do leaders get wrong when making high-risk decisions? October 10, 2024
Executive Insights Life Sciences & Pharma Preparing for Innovation: A Maturity Framework for Artificial Intelligence in Life… August 2, 2024